title: Temporal and geographical trends in indications for implantation of cardiac defibrillators in Europe 1993-1998. Medtronic ICD System Investigators.
abstract: Despite the demonstrated efficacy of implantable cardioverter defibrillators (ICDs) in reducing sudden and total mortality in selected populations, their implantation rates vary greatly between countries. The aim of our study was to analyze temporal and geographical trends in ICD implantations in countries with similar health related expenditure in Western Europe. A total of 2,257 patients from ten European evaluation studies of Medtronic defibrillators and defibrillation electrodes, conducted between 1993 and 1998, representing 12 countries, was included in this analysis. Rates of implantation and clinical characteristics were compared between countries and years of implantation. Rates of implantation differed greatly between Western European countries and did not correlate with indices of health related expenditure (i.e., number of patients per physician and number of patients per hospital bed). However, there was a strong and statistically significant negative correlation between the use of amiodarone and the rates of implantation (r = -0.66, P = 0.02). Temporal trends showed a significant increase in the age of the patients receiving an ICD between 1993 and 1998 (57 +/- 14 vs 61 +/- 12 years, mean +/- SD, P < 0.001). There was also a temporal trend towards an increased incidence of coronary artery disease and a significant decrease in the incidence of cardiomyopathy. There was a temporal increase in implantations in patients with a history of ventricular tachycardia. Despite a general scientific agreement that ICDs are a first line treatment for patients at high risk of sudden cardiac death, their acceptance remains low in several developed countries. This low acceptance may not be entirely related to budget constraint but may also be related to their perceived efficacy by physicians and health authorities.
authors.affiliation: Department of Cardiology, Broussais Hospital, Paris, France.
authors.forename: X
authors.initials: X
authors.lastname: Copie
authors.forename: O
authors.initials: O
authors.lastname: Piot
authors.forename: M A
authors.initials: MA
authors.lastname: Said
authors.forename: T
authors.initials: T
authors.lastname: Lavergne
authors.forename: J
authors.initials: J
authors.lastname: Ollitrault
authors.forename: L
authors.initials: L
authors.lastname: Guize
authors.forename: J Y
authors.initials: JY
authors.lastname: Le Heuzey
mesh_terms: D000638:Amiodarone / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D009202:Cardiomyopathies / Q000150:complications; D003327:Coronary Disease / Q000150:complications; D016757:Death, Sudden, Cardiac; D017147:Defibrillators, Implantable / Q000706:statistics & numerical data / Q000639:trends*; D005060:Europe; D005260:Female; D005102:Health Expenditures; D006295:Health Resources; D006801:Humans; D008297:Male; D008875:Middle Aged; D017180:Tachycardia, Ventricular / Q000150:complications / Q000188:drug therapy / Q000628:therapy
chemical_list: D000889:Anti-Arrhythmia Agents; D000638:Amiodarone